Please assess the completion status of the following clinical trial:

Trial Title: Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Men or women of any racial background~* healthy~* sealevel resident~* age \>= 18 years, =\< 65 years~* SBP\< 130 mmHg and DBP\< 80 mmHg, average of two measures at the sceening visit~* FG \< 100 mg/dl (5.6 mmol/l)~* BMI \< 25~* written informed consent signed~Exclusion Criteria~* engagement in regular exercise training~* smoking habit~* being enrolled in another research study~* any current or previous cardiovascular, metabolic disease or any other cronic disease~* any current treatment for any medical condition~* any medical condition preventing or contraindication exposure to altitude hypoxia~* any gastrointestinal disorder interfering with drug absorption~* known allergy or contraindications to beta-blockers~* pregnant or lactating women; women in reproductive age not using recognized contraceptive methods.~* malignancy within the last 5 years~* drug abuse or alcohol abuse within the last 5 years~* history of noncompliance to medical regimens~* incapacity or unwillingness to sign the informed consent~* participation in any investigational clinical trial within the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Placebo tablets. One tablet twice daily.
- 2: Carvedilol (Type: ACTIVE_COMPARATOR): Carvedilol 25 mg tablets. One tablet twice daily.
- 3: Nebivolol (Type: ACTIVE_COMPARATOR): Nebivolol 5 mg tablets. One nebivolo tablet daily. One placebo tablet daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).